Insmed Inc  (INSM)
Other Ticker:  
Price: $22.0000 $-1.60 -6.780%
Day's High: $23.76 Week Perf: -13.86 %
Day's Low: $ 21.92 30 Day Perf: -11.72 %
Volume (M): 2,457 52 Wk High: $ 32.00
Volume (M$): $ 54,047 52 Wk Avg: $25.06
Open: $23.66 52 Wk Low: $18.31

 Market Capitalization (Millions $) 3,266
 Shares Outstanding (Millions) 148
 Employees 400
 Revenues (TTM) (Millions $) 320
 Net Income (TTM) (Millions $) -747
 Cash Flow (TTM) (Millions $) -373
 Capital Exp. (TTM) (Millions $) 15

Insmed Inc
Insmed Inc. is a biopharmaceutical company that develops and commercializes innovative therapies for patients with unmet medical needs. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed is focused on developing therapies for serious respiratory diseases and rare diseases that have limited treatment options. The company's lead product, ARIKAYCE, is the first and only FDA-approved therapy for patients with Mycobacterium avium complex (MAC) lung disease, a rare and chronic infection that can cause significant damage to the lungs.

The company's pipeline includes several other novel product candidates in various stages of development. INS1007 is being developed for the treatment of non-cystic fibrosis bronchiectasis, a chronic and debilitating respiratory disease. INS1009 is being developed for the treatment of rare pulmonary diseases, including pulmonary alveolar proteinosis and alpha-1 antitrypsin deficiency.

Insmed is also developing therapies for rare diseases outside of the respiratory space. The company's pipeline includes INS1001, a potential treatment for rare genetic disorders, including Pantothenate kinase-associated neurodegeneration (PKAN) and other pantothenate kinase-associated disorders.

The company has a strong commitment to research and development and invests heavily in this area. Insmed has a global team of scientists and researchers who are dedicated to discovering and developing new therapies for patients in need.

Insmed has experienced significant growth in recent years, with a market cap of over $5 billion as of early 202 The company has a strong financial position, with a cash and cash equivalents balance of $499 million as of September 30, 2020.

Overall, Insmed is a leading biopharmaceutical company focused on developing and commercializing innovative therapies for serious respiratory diseases and rare diseases. The company has a strong commitment to research and development and is well-positioned for continued growth and success in the biopharmaceutical industry.

   Company Address: 700 US Highway 202/206 Bridgewater 8807 NJ
   Company Phone Number: 977-9900   Stock Exchange / Ticker: NASDAQ INSM


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Insmed Inc

Insmed Inc. Boasts Impressive 22.269% Revenue Surge in Fiscal First Quarter of 2024

Insmed Inc, a major player in the pharmaceutical industry, recently released its financial results for the period between January and March 31, 2024. While the company showcased a commendable decrease in its loss per share compared to the previous year, and a growth in revenue, a closer look reveals concerning trends that reflect a bearish outlook for the company. This article will delve into Insmed Inc's financial performance, highlighting certain key aspects that raise doubts about its long-term profitability.
Decreased Loss per Share Not Fully Encouraging:
Insmed Inc managed to decrease its loss per share to $-1.06 during the current reporting period, compared to $-1.17 in the previous year. This improvement may seem positive on the surface, but a closer examination reveals only a marginal decline. Furthermore, it is important to note that the company's EPS improved only slightly, from $-1.11 in the preceding reporting period. This indicates that Insmed Inc is struggling to rein in its losses and generate sustainable profits.

Insmed Inc

2. The Real Story Behind Insmed Inc's Revenue Surge: Why Profitability Remains Elusive

In a year that proved to be challenging for many companies in the major pharmaceutical preparations sector, Insmed Inc stands out as a beacon of hope. Despite incurring a net loss of $1.11 per share in the financial time-frame closing December 31, 2023, the company's revenue experienced an impressive surge of 48.273% to $85.66 million from the corresponding quarter a year prior. This groundbreaking achievement has garnered attention and admiration from investors and industry experts alike.
Outperforming Its Peers
Insmed Inc's exceptional performance in the major pharmaceutical preparations sector has left its competitors in the dust. While the industry experienced an average contraction of 8.93% in revenue, Insmed Inc successfully defied the trend by exhibiting significant top-line improvement. This achievement reflects the strong leadership and strategic decisions made by the company's management team.

Insmed Inc

Pharmaceutical Preparations Company's Spectacular Revenue Jump Signals Promising Future in Financial Third Quarter of 2023

This financial news report highlights the third-quarter financial results of Insmed Inc (INSM) for the year 2023. It examines the revenue growth, deficit, earnings per share, net deficit, inventory levels, accounts receivable, and future prospects of the company. Additionally, it provides an overview of Insmed Inc's recent stock performance.
Financial Results Analysis:
During the third quarter of 2023, Insmed Inc reported a revenue increase of 14.825% compared to the same period last year, amounting to $77.77 million. However, despite the growth in revenue, the company's deficit per share worsened to $-1.11. This represents an extension of the deficit when compared to the previous year's quarter.

Insmed Inc

Insmed Inc Reports Impressive 20% Revenue Rise Amid 2023's Second Quarter, Outperforming Major Pharmaceutical Sector Contemporaries

Insmed Inc, a major player in the pharmaceutical preparations sector, recently announced its financial results for the second quarter of 2023. The company reported a significant surge in revenue, outpacing its competitors in the sector. However, despite the revenue growth, there was an increase in losses per share. This article will analyze the financial results of Insmed Inc and provide an overview of the company's current stock performance.
Financial Results for Q2 2023:
Insmed Inc witnessed a remarkable 20.227% increase in revenue during the second quarter of 2023. The company's revenue reached $78.41 million, surpassing the comparable period from the previous year. This growth rate was substantially higher than the average revenue rise of 1.81% experienced by other major pharmaceutical preparations companies in the sector.

Insmed Inc

Insmed Inc. Plummets Further Into Financial Abyss Despite Revenue Surge in Q1 2023

Insmed Inc. (INSM) has reported a disappointing financial first quarter for 2023, with losses expanding to $-1.17 per share, compared to $-0.80 per share a year ago and $-1.17 per share in the prior reporting period. This is a worrying trend for investors, as the company's losses continue to grow at an alarming rate.
To make matters worse, the company's revenue has only seen a modest rise of 19.911%, from $53.11 million to $63.68 million in the comparable period a year ago, and a sequential increase of just 10.224% from $57.77 million. This is by no means a significant enough increase to offset the substantial losses that the company is reporting.
In the financial first quarter of 2023, Insmed recorded a net loss of $-159.764 million, significantly higher than the $-94.621 million from a year ago. This is a clear indication that the company's operations are deteriorating, and management may be struggling to turn the business around.


Insmed Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Insmed Inc does not provide revenue guidance.

Earnings Outlook
Insmed Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com